首页> 美国卫生研究院文献>Scientific Reports >Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status
【2h】

Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status

机译:混合性浸润性导管和小叶癌具有明显的临床特征按雌激素受体状态分层可预测预后较差

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In order to investigate clinicopathological characteristics and prognosis of mixed invasive ductal and lobular carcinoma (IDC-L), 209,109 primary breast cancer patients diagnosed with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC) or IDC-L were included. It was found that IDC-L patients had lower tumor grade and higher hormone receptor positive proportions than IDC patients. Moreover, IDC-L patients were younger and had a similar hormone receptor status compared with ILC patients. Kaplan-Meier plots showed that the breast cancer-specific survival (BCSS) of IDC-L patients was significantly better than IDC patients (P < 0.001) and tended to be better than ILC patients (P = 0.166). However, after adjusting for clinicopathological factors, survival advantage of IDC-L disappeared. Subgroup analysis indicated that IDC-L had higher hazard ratios (HRs) than IDC in grade 1, grade 2, ER-positive and ER-negative subgroups. Survival analysis in ER-positive and ER-negative subgroups showed that IDC-L predicted a worse prognosis than IDC. In conclusion, IDC-L is a distinct histological subtype compared with IDC and ILC. Lower grade and higher ER-positive proportions mainly contribute to its better prognosis. In both ER-positive and ER-negative subgroups, IDC-L predicts worse prognosis than IDC, which suggested the inadequacy of IDC-based therapy and the need of escalated therapy.
机译:为了研究混合浸润性导管和小叶癌(IDC-L)的临床病理特征和预后,纳入了209,109名被诊断为浸润性导管癌(IDC),浸润性小叶癌(ILC)或IDC-L的原发性乳腺癌患者。发现IDC-L患者比IDC患者具有更低的肿瘤等级和更高的激素受体阳性比例。此外,与ILC患者相比,IDC-L患者更年轻,激素受体状态相似。 Kaplan-Meier图显示IDC-L患者的乳腺癌特异性生存率(BCSS)明显优于IDC患者(P <0.001),并且倾向于优于ILC患者(P = 0.166)。但是,在调整了临床病理因素后,IDC-L的生存优势消失了。亚组分析表明,在1级,2级,ER阳性和ER阴性的亚组中,IDC-L的危险比(HRs)比IDC高。 ER阳性和ER阴性亚组的生存分析表明,IDC-L的预后比IDC差。总之,与IDC和ILC相比,IDC-L是一种独特的组织学亚型。较低等级和较高的ER阳性比例主要有助于其更好的预后。在ER阳性和ER阴性亚组中,IDC-L预测的预后均较IDC差,这提示基于IDC的治疗不足且需要逐步治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号